Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis

Yukito Ichinose, Tokujiro Yano, Hiroshi Asoh, Hideki Yokoyama, Yasuro Fukuyama, Jun Miyagi, Shinji Kuninaka, Yasuhiro Terazaki

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background and Objectives: We recently developed a new intraoperatire intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in non-small cell lung cancer patients. In the present study, the efficacy and adverse events of this treatment as well as the pharmacokinetics of cisplatin in the blood after the treatment were evaluated. Patients and Methods: Twenty-one patients received the treatment for 15 minutes after completing the intrathoracic surgical procedures. The total and free platinum levels in the blood of five patients were then measured. As a control, 29 patients without such treatment were reviewed retrospectively. Results: The survival rates in the treatment and non- treatment groups were similar. The pleural disease free survival of the treated patients was, however, significantly higher than that of the non- treated patients. Such pleural disease as effusion and the growth of the pleural disseminated tumors only appeared in three of the 21 (14%) treated patients while 26 of 29 (90%) non-treated patients had clinically detected pleural disease. The blood platinum levels after the treatment were extremely low and such low levels probably induced no systemic adverse events after the treatment. The only adverse event of this treatment was an increase in the postoperative drainage volume. Conclusions: These observations seem to suggest that intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy can, at least, delay the appearance of the pleural disease without any adverse events.

Original languageEnglish
Pages (from-to)196-200
Number of pages5
JournalJournal of Surgical Oncology
Volume66
Issue number3
DOIs
Publication statusPublished - 1997 Nov
Externally publishedYes

Fingerprint

Pleurisy
Cisplatin
Pleural Diseases
Neoplasms
Therapeutics
Thoracotomy
Platinum
Pleural Effusion
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Drainage
Survival Rate
Pharmacokinetics

Keywords

  • Carcinomatous pleuritis
  • Cisplatin
  • Intracavitary chemotherapy
  • Malignant effusion
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis. / Ichinose, Yukito; Yano, Tokujiro; Asoh, Hiroshi; Yokoyama, Hideki; Fukuyama, Yasuro; Miyagi, Jun; Kuninaka, Shinji; Terazaki, Yasuhiro.

In: Journal of Surgical Oncology, Vol. 66, No. 3, 11.1997, p. 196-200.

Research output: Contribution to journalArticle

Ichinose, Y, Yano, T, Asoh, H, Yokoyama, H, Fukuyama, Y, Miyagi, J, Kuninaka, S & Terazaki, Y 1997, 'Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis', Journal of Surgical Oncology, vol. 66, no. 3, pp. 196-200. https://doi.org/10.1002/(SICI)1096-9098(199711)66:3<196::AID-JSO8>3.0.CO;2-7
Ichinose, Yukito ; Yano, Tokujiro ; Asoh, Hiroshi ; Yokoyama, Hideki ; Fukuyama, Yasuro ; Miyagi, Jun ; Kuninaka, Shinji ; Terazaki, Yasuhiro. / Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis. In: Journal of Surgical Oncology. 1997 ; Vol. 66, No. 3. pp. 196-200.
@article{f9027c695c8f4deaaf38410816bdb6bf,
title = "Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis",
abstract = "Background and Objectives: We recently developed a new intraoperatire intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in non-small cell lung cancer patients. In the present study, the efficacy and adverse events of this treatment as well as the pharmacokinetics of cisplatin in the blood after the treatment were evaluated. Patients and Methods: Twenty-one patients received the treatment for 15 minutes after completing the intrathoracic surgical procedures. The total and free platinum levels in the blood of five patients were then measured. As a control, 29 patients without such treatment were reviewed retrospectively. Results: The survival rates in the treatment and non- treatment groups were similar. The pleural disease free survival of the treated patients was, however, significantly higher than that of the non- treated patients. Such pleural disease as effusion and the growth of the pleural disseminated tumors only appeared in three of the 21 (14{\%}) treated patients while 26 of 29 (90{\%}) non-treated patients had clinically detected pleural disease. The blood platinum levels after the treatment were extremely low and such low levels probably induced no systemic adverse events after the treatment. The only adverse event of this treatment was an increase in the postoperative drainage volume. Conclusions: These observations seem to suggest that intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy can, at least, delay the appearance of the pleural disease without any adverse events.",
keywords = "Carcinomatous pleuritis, Cisplatin, Intracavitary chemotherapy, Malignant effusion, Non-small cell lung cancer",
author = "Yukito Ichinose and Tokujiro Yano and Hiroshi Asoh and Hideki Yokoyama and Yasuro Fukuyama and Jun Miyagi and Shinji Kuninaka and Yasuhiro Terazaki",
year = "1997",
month = "11",
doi = "10.1002/(SICI)1096-9098(199711)66:3<196::AID-JSO8>3.0.CO;2-7",
language = "English",
volume = "66",
pages = "196--200",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis

AU - Ichinose, Yukito

AU - Yano, Tokujiro

AU - Asoh, Hiroshi

AU - Yokoyama, Hideki

AU - Fukuyama, Yasuro

AU - Miyagi, Jun

AU - Kuninaka, Shinji

AU - Terazaki, Yasuhiro

PY - 1997/11

Y1 - 1997/11

N2 - Background and Objectives: We recently developed a new intraoperatire intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in non-small cell lung cancer patients. In the present study, the efficacy and adverse events of this treatment as well as the pharmacokinetics of cisplatin in the blood after the treatment were evaluated. Patients and Methods: Twenty-one patients received the treatment for 15 minutes after completing the intrathoracic surgical procedures. The total and free platinum levels in the blood of five patients were then measured. As a control, 29 patients without such treatment were reviewed retrospectively. Results: The survival rates in the treatment and non- treatment groups were similar. The pleural disease free survival of the treated patients was, however, significantly higher than that of the non- treated patients. Such pleural disease as effusion and the growth of the pleural disseminated tumors only appeared in three of the 21 (14%) treated patients while 26 of 29 (90%) non-treated patients had clinically detected pleural disease. The blood platinum levels after the treatment were extremely low and such low levels probably induced no systemic adverse events after the treatment. The only adverse event of this treatment was an increase in the postoperative drainage volume. Conclusions: These observations seem to suggest that intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy can, at least, delay the appearance of the pleural disease without any adverse events.

AB - Background and Objectives: We recently developed a new intraoperatire intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in non-small cell lung cancer patients. In the present study, the efficacy and adverse events of this treatment as well as the pharmacokinetics of cisplatin in the blood after the treatment were evaluated. Patients and Methods: Twenty-one patients received the treatment for 15 minutes after completing the intrathoracic surgical procedures. The total and free platinum levels in the blood of five patients were then measured. As a control, 29 patients without such treatment were reviewed retrospectively. Results: The survival rates in the treatment and non- treatment groups were similar. The pleural disease free survival of the treated patients was, however, significantly higher than that of the non- treated patients. Such pleural disease as effusion and the growth of the pleural disseminated tumors only appeared in three of the 21 (14%) treated patients while 26 of 29 (90%) non-treated patients had clinically detected pleural disease. The blood platinum levels after the treatment were extremely low and such low levels probably induced no systemic adverse events after the treatment. The only adverse event of this treatment was an increase in the postoperative drainage volume. Conclusions: These observations seem to suggest that intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy can, at least, delay the appearance of the pleural disease without any adverse events.

KW - Carcinomatous pleuritis

KW - Cisplatin

KW - Intracavitary chemotherapy

KW - Malignant effusion

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0030712421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030712421&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-9098(199711)66:3<196::AID-JSO8>3.0.CO;2-7

DO - 10.1002/(SICI)1096-9098(199711)66:3<196::AID-JSO8>3.0.CO;2-7

M3 - Article

VL - 66

SP - 196

EP - 200

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -